AP619A - Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction. - Google Patents

Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction. Download PDF

Info

Publication number
AP619A
AP619A APAP/P/1995/000757A AP9500757A AP619A AP 619 A AP619 A AP 619A AP 9500757 A AP9500757 A AP 9500757A AP 619 A AP619 A AP 619A
Authority
AP
ARIPO
Prior art keywords
hyaluronic acid
human
administration
pharmaceutically acceptable
effective amount
Prior art date
Application number
APAP/P/1995/000757A
Other languages
English (en)
Other versions
AP9500757A0 (en
Inventor
Eva Anne Turley
Samuel Simon Asculai
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of AP9500757A0 publication Critical patent/AP9500757A0/xx
Application granted granted Critical
Publication of AP619A publication Critical patent/AP619A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1995/000757A 1994-08-24 1995-08-14 Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction. AP619A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002130762A CA2130762C (en) 1994-08-24 1994-08-24 Treatment of disease and conditions associated with macrophage infiltration

Publications (2)

Publication Number Publication Date
AP9500757A0 AP9500757A0 (en) 1995-10-31
AP619A true AP619A (en) 1997-10-10

Family

ID=4154227

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1995/000757A AP619A (en) 1994-08-24 1995-08-14 Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.

Country Status (14)

Country Link
EP (1) EP0777487B1 (ja)
JP (1) JP4111537B2 (ja)
KR (1) KR970705402A (ja)
CN (1) CN1131539A (ja)
AP (1) AP619A (ja)
AT (1) ATE212850T1 (ja)
AU (1) AU701014B2 (ja)
CA (1) CA2130762C (ja)
DE (1) DE69525349T2 (ja)
ES (1) ES2172589T3 (ja)
HU (1) HUT76895A (ja)
IL (1) IL114915A0 (ja)
WO (1) WO1996005845A2 (ja)
ZA (1) ZA957056B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
EP0914133B1 (en) * 1996-03-14 2003-07-23 The Governors Of The University Of Alberta Use of hyaluronan (ha) for cell mobilization
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
DE69738948D1 (de) 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP1165097B1 (en) * 1999-02-01 2007-05-02 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and their use
CA2365767A1 (en) * 1999-03-15 2000-09-21 Trustees Of Boston University Angiogenesis inhibition
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
BR112017010110A2 (pt) 2014-11-21 2018-01-30 Bristol-Myers Squibb Company anticorpos contra cd73 e usos do mesmo
CN111182902A (zh) * 2017-09-01 2020-05-19 黄玲惠 用于治疗缺血的黏性组合物
JP7333919B2 (ja) * 2017-09-05 2023-08-28 エクセル メッド、エルエルシー 虚血を治療するためのヘパリン組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057118A2 (fr) * 1981-01-27 1982-08-04 Thomson-Csf Dispositif électromécanique d'impression pour imprimante du type série-parallèle
AP175A (en) * 1989-09-21 1992-04-03 Norpharmco Inc Combination and formulations and the administration thereof to a mammal for the treatment of conditions and disease.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
AU3721793A (en) * 1992-02-24 1993-09-13 Paul L. Simmons Biodegradable germicide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057118A2 (fr) * 1981-01-27 1982-08-04 Thomson-Csf Dispositif électromécanique d'impression pour imprimante du type série-parallèle
AP175A (en) * 1989-09-21 1992-04-03 Norpharmco Inc Combination and formulations and the administration thereof to a mammal for the treatment of conditions and disease.

Also Published As

Publication number Publication date
AP9500757A0 (en) 1995-10-31
CA2130762A1 (en) 1996-02-25
HUT76895A (en) 1997-12-29
ATE212850T1 (de) 2002-02-15
WO1996005845A3 (en) 1996-04-11
ZA957056B (en) 1996-03-26
JP4111537B2 (ja) 2008-07-02
EP0777487A1 (en) 1997-06-11
DE69525349T2 (de) 2002-10-31
WO1996005845A2 (en) 1996-02-29
IL114915A0 (en) 1995-12-08
DE69525349D1 (de) 2002-03-21
CA2130762C (en) 1999-07-06
EP0777487B1 (en) 2002-02-06
ES2172589T3 (es) 2002-10-01
KR970705402A (ko) 1997-10-09
JPH10506884A (ja) 1998-07-07
AU701014B2 (en) 1999-01-21
AU3107095A (en) 1996-03-14
CN1131539A (zh) 1996-09-25

Similar Documents

Publication Publication Date Title
Dixon et al. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee
EP0754460B1 (en) Antiinflammatory agents
US9561260B2 (en) Compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid
US5614506A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US20070054878A1 (en) Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis
HU220758B1 (hu) Eljárás hialuronsavat és nem szteroid gyulladásgátlót tartalmazó, rák kezelésére alkalmas gyógyászati készítmények előállítására
US5674857A (en) Use of hyaluronic acid to repair ischemia reperfusion damage
JPH09512797A (ja) 癌の治療および転移の予防
AP619A (en) Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
US20170056561A1 (en) Compositions for the treatment of joints
AU2004224510B2 (en) Remedy for nerve damage
US5834444A (en) Hyaluronic acid and salts thereof inhibit arterial restenosis
US5767106A (en) Treatment of disease and conditions associated with macrophage infiltration
US5817642A (en) Clearing of atherosclerosis
HU227067B1 (en) Use of hyaluronic acid for preparing pharmaceutical compositions to prevent arterial restenosis
JP2667441B2 (ja) 血管内皮細胞増殖抑制剤
JP3811500B2 (ja) 動脈硬化の除去のためのヒアルロン酸を含む薬剤組成物
KR100531721B1 (ko) 중추 신경계 외상 예방과 치료를 위한 저분자량 헤파린의사용
JPH07507289A (ja) 抗炎症剤
CA2167044C (en) Oral administration of effective amounts of forms of hyaluronic acid